Item 8.01 Other Events.

Sangamo Therapeutics, Inc. is filing this report for the purpose of filing a copy of the slides containing updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for patients with severe hemophilia A, that were presented on December 7, 2020 at the 62nd American Society of Hematology (ASH) Annual Meeting (the "Data Presentation"). A copy of the Data Presentation is attached as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.




Exhibit
  No.       Description

99.1          2020 American Society of Hematology (ASH) Annual Meeting Data
            Presentation

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses